ARTIVION INC (AORT) Stock News
NYSE:AORT - New York Stock Exchange, Inc. - US2289031005 - Common Stock - Currency: USD
AORT Latest News, Press Relases and Analysis
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
ICU Medical (ICUI) Q4 Earnings Report Preview: What To Look For
Medical device company ICU Medical (NASDAQ:ICUI) will be reporting results tomorrow after market close. Here’s what you need to know.
Artivion (AORT) Stock Trades Down, Here Is Why
Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's expectations. While revenue did grow 4% year-on-year, it still fell short, partly due to the late-November cybersecurity incident that disrupted operations.
Artivion (AORT) Stock Trades Down, Here Is Why
Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's expectations. While revenue did grow 4% year-on-year, it still fell short, partly due to the late-November cybersecurity incident that disrupted operations.
Artivion (NYSE:AORT) Misses Q4 Sales Targets
Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s full-year revenue guidance of $427.5 million at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP loss of $0 per share was significantly below analysts’ consensus estimates.
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of...
Artivion Reports Third Quarter 2024 Financial Results
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9%...
Artivion (NYSE:AORT) Q3 Earnings: Leading The Medical Devices & Supplies - Cardiology, Neurology, Vascular Pack
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers.
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and...
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS...
Artivion to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
AORT Stock Earnings: Artivion Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artivion (NYSE:AORT) just reported results for the second quarter of 2024.Artiv...
AORT Stock Earnings: Artivion Beats EPS, Beats Revenue for Q2 2024
AORT stock results show that Artivion beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024...
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS...
Artivion Reports Second Quarter 2024 Financial Results
Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of...
Artivion to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024...
3 Earnings All-Stars With More Room to Run
Travelers, Seagate Technology and Artivion are top earnings outperformers poised for further growth and significant returns.
Artivion Amends Agreements with Endospan
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its...